Stockreport

Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program [Yahoo! Finance]

Tango Therapeutics, Inc.  (TNGX) 
PDF for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ: TNGX; Tango), has announced that the phase 1/2 clini [Read more]